10:07:08 AM

LSTA Stock News

LSTA - Lisata Therapeutics Inc

05/24/23 8:00 AM

Nasdaq : LSTA

clinical triallow float

Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1

RHEA-AI

positive

05/09/23 4:05 PM

Nasdaq : LSTA

earningslow float

Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid

RHEA-AI

neutral

05/02/23 9:07 AM

Nasdaq : LSTA

conferencesearningslow float

Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the

RHEA-AI

neutral

04/27/23 9:00 AM

Nasdaq : LSTA

conferenceslow float

Lisata Therapeutics Announces Participation in Upcoming Conferences in May

RHEA-AI

neutral

04/20/23 8:30 AM

Nasdaq : LSTA

low float

Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

RHEA-AI

neutral

04/19/23 8:30 AM

Nasdaq : LSTA

conferenceslow float

Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

RHEA-AI

neutral

04/18/23 8:30 AM

Nasdaq : LSTA

low float

Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the

RHEA-AI

neutral

03/30/23 4:05 PM

Nasdaq : LSTA

earningslow float

Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid

RHEA-AI

neutral

03/23/23 8:30 AM

Nasdaq : LSTA

conferencesearningslow float

Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time

RHEA-AI

neutral

02/01/23 8:30 AM

Nasdaq : LSTA

conferenceslow float

Lisata Therapeutics Announces Participation in Upcoming Conferences in February

RHEA-AI

neutral

1 2 Next

LSTA Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.caladrius.com
CeoDavid Mazzo
Security nameLisata Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code8731
Employees27
Address110 Allen Rd
StateNew Jersey
CityBasking Ridge
Zip07920-4500
CountryUS
Phone19088420100

About Lisata Therapeutics Inc

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. It is developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Its technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication. The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; OLOGO™ (formerly CLBS14), a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”).